Unknown

Dataset Information

ExpHRD: an individualized, transcriptome-based prediction model for homologous recombination deficiency assessment in cancer.


ABSTRACT:

Background

Homologous recombination deficiency (HRD) stands as a clinical indicator for discerning responsive outcomes to platinum-based chemotherapy and poly ADP-ribose polymerase (PARP) inhibitors. One of the conventional approaches to HRD prognostication has generally centered on identifying deleterious mutations within the BRCA1/2 genes, along with quantifying the genomic scars, such as Genomic Instability Score (GIS) estimation with scarHRD. However, the scarHRD method has limitations in scenarios involving tumors bereft of corresponding germline data. Although several RNA-seq-based HRD prediction algorithms have been developed, they mainly support cohort-wise classification, thereby yielding HRD status without furnishing an analogous quantitative metric akin to scarHRD. This

SUBMITTER: Lee JJ 

PROVIDER: S-EPMC11241885 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature